Ovid Therapeutics: Bullish Outlook After PIPE Financing for CNS Drug Development

Ovid Therapeutics is a CNS drug developer with a pipeline focused on treating disorders linked to neuronal hyperexcitability. The company has two main mechanisms in development: a GABA-AT inhibitor for uncontrolled epilepsy and a KCC2 inhibitor for treating neuropsychiatric and neurological diseases. After a PIPE (Private Investment in Public Equity) deal, Ovid is now better capitalized to advance its promising pipeline. The company has a differentiated approach and two moonshot programs that could have significant potential.